Advertisement
Canada markets closed

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7321
    +0.0001 (+0.01%)
     

  • CRUDE OIL

    83.45
    +0.09 (+0.11%)
     

  • Bitcoin CAD

    91,003.37
    -479.99 (-0.52%)
     

  • CMC Crypto 200

    1,430.28
    +15.52 (+1.10%)
     

  • GOLD FUTURES

    2,336.30
    -5.80 (-0.25%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0520 (-1.12%)
     

  • NASDAQ futures

    17,709.00
    +102.25 (+0.58%)
     

  • VOLATILITY

    15.69
    -1.25 (-7.38%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    38,247.35
    +695.19 (+1.85%)
     

  • CAD/EUR

    0.6834
    -0.0002 (-0.03%)
     

NUVA Announces Licensing Agreements for 48 Generic Drugs for Canadian Markets

Marketwired

VANCOUVER, BRITISH COLUMBIA--(Marketwired - April 16, 2014) - NUVA PHARMACEUTICALS INC. (the "Company" or "NUVA") (TSX VENTURE:NPH) (NUVPF) is pleased to announce that it has signed Cross Referencing Agreements (the "CRAs") for prescription generic products for Canadian markets. These agreements cover 48 prescription generic products and are for acute and chronic diseases.

The company has signed CRAs with three large pharmaceutical companies for multiple products in the prescription generic drug lines. NUVA will market and sell these new product lines under its own label.

NUVA is in the process of securing a Drug Establishment License (the "DEL") from Health Canada. Upon receipt of the DEL, NUVA will start filing for regulatory approval of these products with Health Canada. NUVA will also initiate ordering, packaging and art work related processes for these generic products. NUVA expects to build its "NUVA" label Generic portfolio for the Canadian Market apart from the "NUVA" range of Over-the-Counter products.

On behalf of:

ADVERTISEMENT

NUVA PHARMACEUTICALS INC.

Jamie Lewin, Director and CFO

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves NUVA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. NUVA generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "plan," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to NUVA as of the date of this release, and NUVA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of NUVA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.